2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Paolo Ghia, MD, PhD, discusses the results from the minimal residual disease cohort of the phase 2 CAPTIVATE study in chronic lymphocytic leukemia that were presented during the 2021 ASH Annual Meeting & Exposition.
Paolo Ghia, MD, PhD, full professor, Medical Oncology, head, Strategic Research Program on CLL, Università Vita Salute San Raffaele, deputy director, Division of Experimental Oncology, San Raffaele Scientific Institute, discusses the results from the minimal residual disease (MRD) cohort of the phase 2 CAPTIVATE study (NCT02910583) in chronic lymphocytic leukemia (CLL) that were presented during the 2021 ASH Annual Meeting & Exposition.
Ghia presented the 2-year disease-free survival (DFS) update of the CAPTIVATE study, which included freedom from progressive disease, freedom from death, and freedom from MRD relapse, Ghia says. The results of the follow-up revealed that the 2-year DFS survival rate was 100% with ibrutinib (Imbruvica) plus venetoclax (Venclexta) vs 95% with placebo in patients with CLL. Moreover, these findings wereidentical to those seen at the 1-year analysis of the data, Ghia explains.
These data suggest that patients who achieved undetectable MRD can safely interrupt treatment without significant difference from the efficacy of continuous ibrutinib, Ghia concludes.